Eli Lilly and Company $LLY Shares Sold by PSI Advisors LLC

PSI Advisors LLC lessened its position in shares of Eli Lilly and Company (NYSE:LLY) by 12.2% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,510 shares of the company’s stock after selling 625 shares during the quarter. Eli Lilly and Company comprises 1.3% of PSI Advisors LLC’s investment portfolio, making the stock its 12th biggest holding. PSI Advisors LLC’s holdings in Eli Lilly and Company were worth $5,409,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. Hardy Reed LLC lifted its stake in Eli Lilly and Company by 173.9% in the second quarter. Hardy Reed LLC now owns 3,509 shares of the company’s stock valued at $4,209,000 after buying an additional 2,228 shares during the last quarter. Essential Planning LLC. increased its holdings in shares of Eli Lilly and Company by 0.4% in the 2nd quarter. Essential Planning LLC. now owns 2,850 shares of the company’s stock valued at $3,418,000 after acquiring an additional 11 shares during the period. Oppenheimer & Co. Inc. increased its stake in Eli Lilly and Company by 6.6% in the second quarter. Oppenheimer & Co. Inc. now owns 78,682 shares of the company’s stock valued at $94,374,000 after purchasing an additional 4,898 shares during the period. Halter Ferguson Financial Inc. increased its position in Eli Lilly and Company by 7.8% in the 2nd quarter. Halter Ferguson Financial Inc. now owns 8,287 shares of the company’s stock valued at $9,940,000 after acquiring an additional 601 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of Eli Lilly and Company by 336.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 145,790 shares of the company’s stock valued at $176,803,000 after purchasing an additional 112,418 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,182.24 on Friday. The stock has a fifty day moving average price of $1,170.82 and a 200 day moving average price of $1,052.76. The stock has a market cap of $1.11 trillion, a PE ratio of 39.67, a P/E/G ratio of 1.43 and a beta of 0.51. Eli Lilly and Company has a 1 year low of $685.15 and a 1 year high of $1,249.45. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.Eli Lilly and Company’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same period in the previous year, the business earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 36.33 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 23.22%.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

LLY has been the subject of several analyst reports. JPMorgan Chase & Co. increased their price target on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Tuesday, July 7th. Barclays boosted their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Cantor Fitzgerald upped their price target on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Rothschild & Co Redburn increased their price target on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Finally, Jefferies Financial Group raised their price objective on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research note on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,292.18.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. regulator approved Lilly’s once-daily oral weight-loss pill, Foundayo (orforglipron), giving the company a potentially important first-mover advantage for an obesity pill in Europe. The approval expands Lilly’s addressable market beyond injectable treatments such as Mounjaro and Zepbound. Eli Lilly Just Scored Europe’s First Weight Loss Pill Approval
• Positive Sentiment: Lilly is expanding its obesity pipeline with a new Phase 1 macupatide study in Japan. Although early-stage, the trial reinforces the company’s efforts to develop additional weight-management therapies and support long-term growth. Lilly Expands Obesity Pipeline With Fresh Macupatide Trial in Japan
• Positive Sentiment: Recent earnings showed continued operating momentum: quarterly revenue rose about 48% year over year to roughly $23 billion, while adjusted EPS beat expectations. Growth was led by Mounjaro, Zepbound and other key medicines, and management raised full-year 2026 guidance. Foundayo also generated an initial $98 million in quarterly sales. 5 Revealing Analyst Questions From Eli Lilly’s Q2 Earnings Call
• Neutral Sentiment: Analysts continue to view LLY as a fundamental leader, with reported price targets generally above the current trading level. However, the stock is approaching a technical buy point after a large earnings-driven advance, making valuation and chart resistance important near-term considerations. Eli Lilly Stock Nears Buy Point After Earnings-Fueled Gains
• Negative Sentiment: Insider-selling headlines may be adding pressure: executives have sold shares in recent months, including a reported 2,000-share sale by CFO and Chief Accounting Officer Donald Zakrowski. Lilly also trades at a demanding earnings multiple, leaving the stock sensitive to profit-taking or any signs of slower obesity-drug growth. Donald Zakrowski Sells 2,000 Shares of Eli Lilly Stock

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.